Prosecution Insights
Last updated: November 20, 2026
Application No. 18/601,981

METHODS AND KITS FOR PREPARING A SAMPLE COMPRISING ONE OR MORE RNA MOLECULES FOR SEQUENCING

Non-Final OA §102§103
Filed
Mar 11, 2024
Priority
Mar 16, 2023 — provisional 63/490,526
Examiner
GRAY, JESSICA
Art Unit
1682
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Hong Kong University of Science and Technology
OA Round
1 (Non-Final)
0%
Grant Probability
At Risk
1-2
OA Rounds
1y 0m
Est. Remaining
0%
With Interview

Examiner Intelligence

Grants only 0% of cases
0%
Career Allowance Rate
0 granted / 13 resolved
-60.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
35 currently pending
Career history
73
Total Applications
across all art units

Statute-Specific Performance

§101
13.4%
-26.6% vs TC avg
§103
32.6%
-7.4% vs TC avg
§102
11.9%
-28.1% vs TC avg
§112
25.6%
-14.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 13 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Invention I, claims 1-16, in the reply filed on 08/23/2026 is acknowledged. Claims 17-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant’s further species election of 2-Amino-6-Cl-purine-rTP as the specific predefined nucleoside analogue triphosphates is acknowledged. Claims 1-20 are pending. Claims 1-16 are under examination on the merits. Priority This application 18/601,981 filed on 03/11/2024 claims the benefit of provisional U.S. Patent Application No. 63/490,526, filed on 03/16/2023. The priority date of claim 1 and its dependent claims is determined to be 03/16/2023, the filing date of provisional U.S. Patent Application No. 63/490,526. Specification The use of terms which are trade names or marks used in commerce (including Invitrogen™ and TriLink BioTechnologies®), has been noted in this application. The term should be accompanied by the generic terminology; furthermore, the term should be capitalized wherever it appears or, where appropriate, include a proper symbol indicating use in commerce such as ™, SM, or ® following the term. Although the use of trade names and marks used in commerce (i.e., trademarks, service marks, certification marks, and collective marks) are permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as commercial marks. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1, 4, 8, and 13 are rejected under 35 U.S.C. 102(a)(1) and (a)(2) as being anticipated by Winz et al. (Site-specific terminal and internal labeling of RNA by poly(A) polymerase tailing and copper-catalyzed or copper-free strain-promoted click chemistry. 2012. Nucleic Acids Research. Vol. 40: p. 1-13. On IDS dated 04/14/2024). Regarding claim 1, Winz teaches a method of terminal labeling of RNA by poly(A) polymerase tailing, the method comprising modifying an RNA at its 3’-end by a poly(A) polymerase with an azido-derivatized nucleotide (nucleotide analog) (Abstract). Regarding (i), Winz teaches the method comprises combining modified NTPs with poly(A) polymerase to transfer the modified nucleotides to the 3’ termini of the RNA, i.e. forming a first tailed RNA (p. 5, col. 1). Regarding (ii), Winz further teaches the polyadenylation of modified RNA (first tailed RNA) by adding ATP (p. 4, col. 1 and p. 8 col. 1-2 and Fig. 6), which reads on adding a sequence comprising a plurality of adenine nucleotides to form a second tailed RNA. Regarding claim 4, Winz teaches poly(A) polymerase is an E. coli poly(A) polymerase (p. 2, col. 1,p. 8, col. 1, and Figs. 1C and 6). Regarding claim 8, Winz teaches a method of terminal labeling of RNA by poly(A) polymerase tailing, the method comprising modifying an RNA at its 3’-end by a poly(A) polymerase with an azido-derivatized nucleotide (nucleotide analog) (Abstract). Regarding (i), Winz teaches the method comprises combining modified NTPs with poly(A) polymerase to transfer the modified nucleotides to the 3’ termini of the RNA, i.e. forming a first tailed RNA (p. 5, col. 1). Regarding (ii), Winz further teaches the polyadenylation of modified RNA (first tailed RNA) by adding ATP (p. 4, col. 1 and p. 8 col. 1-2 and Fig. 6), which reads on adding a sequence comprising a plurality of adenine nucleotides to form a second tailed RNA. Regarding claim 13, Winz teaches Winz teaches poly(A) polymerase is an E. coli poly(A) polymerase (p. 2, col. 1, p. 8, col. 1, and Figs. 1C and 6). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1, 5, 8, and 14 are rejected under 35 U.S.C. 103 as being unpatentable over Winz et al. (Site-specific terminal and internal labeling of RNA by poly(A) polymerase tailing and copper-catalyzed or copper-free strain-promoted click chemistry. 2012. Nucleic Acids Research. Vol. 40: p. 1-13. On IDS dated 04/14/2024). The teachings of Winz as they relate to claim 1 are stated in the 102 rejection above in this office action. Regarding claim 5, Winz is silent regarding the number of adenine nucleotides. However, It would have been prima facie obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Winz to arrive at the instantly claimed invention. The modification would have entailed optimizing the reaction time to control the length of the poly(A) tail. Optimizing the length of the poly(A) tail, i.e. the number of adenines in the sequence, is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan. One would have been motivated by optimization for downstream applications. There would have been a reasonable expectation of success given the underlying materials and methods are widely known, successfully demonstrated, and commonly used as evidenced by the prior art. There would have been a reasonable expectation of success given the underlying materials and methods are widely known, successfully demonstrated, and commonly used as evidenced by the prior art. The teachings of Winz as they relate to claim 8 are stated in the 102 rejection above in this office action. Regarding claim 14, Winz is silent regarding the number of adenine nucleotides. However, It would have been prima facie obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Winz to arrive at the instantly claimed invention. The modification would have entailed optimizing the reaction time to control the length of the poly(A) tail. Optimizing the length of the poly(A) tail, i.e. the number of adenines in the sequence, is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan. One would have been motivated by optimization for downstream applications. There would have been a reasonable expectation of success given the underlying materials and methods are widely known, successfully demonstrated, and commonly used as evidenced by the prior art.There would have been a reasonable expectation of success given the underlying materials and methods are widely known, successfully demonstrated, and commonly used as evidenced by the prior art. Claims 1-3, 6-7, 8, 11-12, and 15-16 are rejected under 35 U.S.C. 103 as being unpatentable over Winz et al. (Site-specific terminal and internal labeling of RNA by poly(A) polymerase tailing and copper-catalyzed or copper-free strain-promoted click chemistry. 2012. Nucleic Acids Research. Vol. 40: p. 1-13. On IDS dated 04/14/2024) in view of de Fougerolles et al. (US20200164038). The teachings of Winz as they relate to claim 1 are stated in the 102 rejection above in this office action. Regarding claims 2 and 3, Winz does not teach the one or more predefined nucleotide analogue is 2-Amino-6-Cl-purine-rTP. de Fougerolles teaches methods of using modified nucleosides, nucleotides, and nucleic acids. de Fougerolles teaches the method includes incorporating modified adenosines into a polynucleotide (para 201) and that the modified nucleotides and nucleosides may be commercially available nucleoside triphosphates (para 1322). de Fougerolles further teaches in some embodiments, the modified nucleobase is a modified adenine such as 2-amino-6-chloro-purine (para 282), which reads on the nucleoside triphosphate 2-Amino-6-Cl-purine-rTP. It would have been prima facie obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to combine the teachings of Winz and de Fougerolles to arrive at the instantly claimed invention. The modification would have entailed using the modified adenine in the triphosphate form as taught by de Fougerolles in the method of Winz. One would have been motivated by the availability of a previously known modified adenine substitute. Further, one of skill in the art would expect the modified adenine to function as a substrate for poly(A) polymerase with the added advantages of chemical stability and versatility provided by a halopurine modified analog instead of an azide modified analog . There would have been a reasonable expectation of success given the underlying materials and methods are widely known, successfully demonstrated, and commonly used as evidenced by the prior art. Regarding claims 6 and 7, Winz does not teach the one or more predefined nucleotide analogue is 2-Amino-6-Cl-purine-rTP. de Fougerolles teaches methods of using modified nucleosides, nucleotides, and nucleic acids. de Fougerolles teaches the method includes incorporating modified adenosines into a polynucleotide (para 201) and that the modified nucleotides and nucleosides may be commercially available nucleoside triphosphates (para 1322). de Fougerolles further teaches that in some embodiments, the modified nucleobase is a modified adenine such as 2-amino-6-chloro-purine (para 282), which reads on the nucleoside triphosphate 2-Amino-6-Cl-purine-rTP. It would have been prima facie obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to combine the teachings of Winz and de Fougerolles to arrive at the instantly claimed invention. The modification would have entailed using the modified adenine in the triphosphate form as taught by de Fougerolles in the method of Winz. One would have been motivated by the availability of a previously known modified adenine substitute. Further, one of skill in the art would expect the modified adenine to function as a substrate for poly(A) polymerase with the added advantages of chemical stability and versatility provided by a halopurine modified analog instead of an azide modified analog. There would have been a reasonable expectation of success given the underlying materials and methods are widely known, successfully demonstrated, and commonly used as evidenced by the prior art. Winz also does not teach verbatim incubating the sample with the reaction mixture for a predetermined time of at least 5 minutes (claim 6) or for a predetermined time of about 10-20 minutes (claim 7). However, Winz teaches varying and optimizing reaction times with poly(A) polymerase (p. 3, col. 1, p. 6 col. 1 & 2). It would have been prima facie obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Winz to arrive at the instantly claimed invention. The modification would have entailed determining an appropriate incubation time. Such a determination is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan. Further, Winz teaches performing such an optimization repeatedly in the course of optimizing reaction conditions. There would have been a reasonable expectation of success given the underlying materials and methods are widely known, successfully demonstrated, and commonly used as evidenced by the prior art. The teachings of Winz as they relate to claim 8 are stated in the 102 rejection above in this office action. Regarding claims 11 and 12, Winz does not teach the one or more predefined nucleotide analogue is 2-Amino-6-Cl-purine-rTP. de Fougerolles teaches methods of using modified nucleosides, nucleotides, and nucleic acids. de Fougerolles teaches the method includes incorporating modified adenosines into a polynucleotide (para 201) and that the modified nucleotides and nucleosides may be commercially available nucleoside triphosphates (para 1322). de Fougerolles further teaches in some embodiments, the modified nucleobase is a modified adenine such as 2-amino-6-chloro-purine (para 282), which reads on the nucleoside triphosphate 2-Amino-6-Cl-purine-rTP. It would have been prima facie obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to combine the teachings of Winz and de Fougerolles to arrive at the instantly claimed invention. The modification would have entailed using the modified adenine in the triphosphate form as taught by de Fougerolles in the method of Winz. One would have been motivated by the availability of a previously known modified adenine substitute. Further, one of skill in the art would expect the modified adenine to function as a substrate for poly(A) polymerase with the added advantages of chemical stability and versatility provided by a halopurine modified analog instead of an azide modified analog .There would have been a reasonable expectation of success given the underlying materials and methods are widely known, successfully demonstrated, and commonly used as evidenced by the prior art. Regarding claims 15 and 16, Winz does not teach the one or more predefined nucleotide analogue is 2-Amino-6-Cl-purine-rTP. de Fougerolles teaches methods of using modified nucleosides, nucleotides, and nucleic acids. de Fougerolles teaches the method includes incorporating modified adenosines into a polynucleotide (para 201) and that the modified nucleotides and nucleosides may be commercially available nucleoside triphosphates (para 1322). de Fougerolles further teaches in some embodiments, the modified nucleobase is a modified adenine such as 2-amino-6-chloro-purine (para 282), which reads on the nucleoside triphosphate 2-Amino-6-Cl-purine-rTP. It would have been prima facie obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to combine the teachings of Winz and de Fougerolles to arrive at the instantly claimed invention. The modification would have entailed using the modified adenine in the triphosphate form as taught by de Fougerolles in the method of Winz. One would have been motivated by the availability of a previously known modified adenine substitute. Further, one of skill in the art would expect the modified adenine to function as a substrate for poly(A) polymerase with the added advantages of chemical stability and versatility provided by a halopurine modified analog instead of an azide modified analog . There would have been a reasonable expectation of success given the underlying materials and methods are widely known, successfully demonstrated, and commonly used as evidenced by the prior art. Winz also does not teach verbatim incubating the sample with the reaction mixture for a predetermined time of at least 5 minutes (claim 6) or for a predetermined time of about 10-20 minutes (claim 7). However, Winz teaches varying and optimizing reaction times with poly(A) polymerase (p. 3, col. 1, p. 6 col. 1 & 2). It would have been prima facie obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Winz to arrive at the instantly claimed invention. The modification would have entailed determining an appropriate incubation time. Such a determination is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan. Further, Winz teaches performing such an optimization repeatedly in the course of optimizing reaction conditions. There would have been a reasonable expectation of success given the underlying materials and methods are widely known, successfully demonstrated, and commonly used as evidenced by the prior art. Claims 8-10 are rejected under 35 U.S.C. 103 as being unpatentable over Winz et al. (Site-specific terminal and internal labeling of RNA by poly(A) polymerase tailing and copper-catalyzed or copper-free strain-promoted click chemistry. 2012. Nucleic Acids Research. Vol. 40: p. 1-13. On IDS dated 04/14/2024) in view of Oxford Nanopore (“Direct RNA sequencing-sequence-specific” protocol, revision 05/22/2022). The teachings of Winz as they relate to claim 8 are stated in the 102 rejection above in this office action. Regarding claims 9 and 10, Winz teaches additional adapter ligation at the 3’ termini of RNAs previously modified in poly(A) polymerase reactions (second-tailed RNA) (p. 2, col. 2 and Table 5) via addition of an adapter and ligase (p. 4, col. 2). Winz further teaches purification of ligated RNA (p. 4, col. 2). However, Winz does not teach the adapter is a sequencing adapter or purifying the ligated RNA after ligating a sequencing adapter to the one or more second tailed RNA. Regarding claim 10, Winz does not teach a sequencing adapter that comprises an oligo-(dT) overhang. Oxford Nanopore teaches a method for direct RNA sequencing of RNA, the method comprising adding a ligase and Reverse Transcription Adapter (sequencing adapter) (p. 12) to add the adapter to the 3’ end of target RNA (p. 4 Figure). Oxford Nanopore teaches a Reverse Transcription Adapter is designed to ligate to any RNA with a poly(A)-tail (p. 3). Oxford Nanopore further teaches an adapter with an oligo-(dT) overhang for binding to a poly(A) tail (p. 3-4 and Figure p. 4). It would have been prima facie obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to combine the teachings of Winz and Oxford Nanopore to arrive at the instantly claimed invention. The modification would have entailed adding a sequencing adapter to the end of the poly(A) tail generated by the method of Winz. One would have been motivated to add the adapter of Oxford Nanopore for the purpose of sequencing RNAs with a poly(A) tail. There would have been a reasonable expectation of success given the underlying materials and methods are widely known, successfully demonstrated, and commonly used as evidenced by the prior art. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JESSICA GRAY whose telephone number is (571)272-0116. The examiner can normally be reached Monday-Friday 8-5 with second Fridays off. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, WINSTON SHEN can be reached at (571)272-3157. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JESSICA GRAY/Examiner, Art Unit 1682 /WU CHENG W SHEN/Supervisory Patent Examiner, Art Unit 1682
Read full office action

Prosecution Timeline

Mar 11, 2024
Application Filed
Nov 03, 2026
Non-Final Rejection mailed — §102, §103 (current)

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
0%
Grant Probability
0%
With Interview (+0.0%)
3y 9m (~1y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 13 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month